Transcode Therapeutics, Inc. (RNAZ): Free Cash Flow
-$19.52M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$19.52M | n/m | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | -$13.36M | n/m | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | -$18.11M | n/m | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | -$15.86M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$5.52M | n/a | 2023-03-31, From 2021-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | -$19.52M | n/m |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | -$8.98M | n/a |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$47.22M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$52.99M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | -$180.0K | n/m |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | -$54.54M | n/m |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | -$47.21M | n/m |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | -$64.50M | n/m |
| Precigen, Inc. (PGEN) | 2025-12-31 | -$89.83M | n/m |
Compare RNAZ, APUS, ACRS, AQST side by side · Screen every company in Pharmaceutical Preparations ↗